Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in mice

British Journal of Anaesthesia

Volumn 105, Issue 5, 2010, Pages 668-674

  Nguyen, T L ^a   Nam, Y S ^a   Lee, S Y ^a   Kim, H C ^b   Jang, C G ^a  

^a Sungkyunkwan University   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

capsazepine; hot plate test; morphine; transient receptor potential vanilloid type 1; withdrawal symptoms

Indexed keywords

CAPSAZEPINE; MORPHINE; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERANCE; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

EID: 77958183756     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeq212     Document Type: Article

References (40)

1. Schumacher MA. Opioid analgesics and antagonists. In: Katzung BG, ed. Basic and Clinical Pharmacology. New York: McGraw-Hill, 2007;489-507
2. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998;21:531-43
3. Sasamura T, Sasaki M, Tohda C, Kuraishi Y. Existence of capsaicinsensitive glutamatergic terminals in rat hypothalamus. Neuroreport 1998;9:2045-8
4. 3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res 2004;995:176-83
5. Koulchitsky SV, Azev OA, Gourine AV, Kulchitsky VA. Capsaicinsensitive area in the ventral surface of the rat medulla. Neurosci Lett 1994;182:129-32
6. Bevan S, Hothi S, Hughes G, et al. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol 1992;107:544-52
7. Jerman JC, Brough SJ, Prinjha R, Harries MH, Davis JB, Smart D. Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology. Br J Pharmacol 2000;130:916-22
8. Urban L, Dray A. Capsazepine, a novel capsaicin antagonist, selectively antagonises the effects of capsaicin in the mouse spinal cord in vitro. Neurosci Lett 1991;134:9-11
9. Perkins MN, Campbell EA. Capsazepine reversal of the antinociceptive action of capsaicin in vivo. Br J Pharmacol 1992;107:329-33
10. Jancso G, Jancso-Gabor A. Effect of capsaicin on morphine analgesia-possible involvement of hypothalamic structures. Naunyn Schmiedebergs Arch Pharmacol 1980;311:285-8
11. Bevan S, Szolcsanyi J. Sensory neuron-specific actions of capsaicin: mechanisms and applications. Trends Pharmacol Sci 1990;11:330-3
12. Ko MC, Johnson MD, Butelman ER, Willmont KJ, Mosberg HI, Woods JH. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. J Pharmacol Exp Ther 1999;291:1113-20
13. Wollemann M, Ioja E, Benyhe S. Capsaicin inhibits the in vitro binding of peptides selective for mu-and kappa-opioid, and nociceptin-receptors. Brain Res Bull 2008;77:136-42
14. Chen SR, Pan HL. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia. J Neurophysiol 2006;95:3086-96
15. Chen Y, Geis C, Sommer C. Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway. J Neurosci 2008;28:5836-45
16. Sharpe LG, Jaffe JH. Neonatal capsaicin modifies morphine withdrawal signs in the rat. Neurosci Lett 1986;71:213-8
17. Donnerer J. Primary sensory neurones and naloxone-precipitated morphine withdrawal. Br J Pharmacol 1989;96:767-72
18. Sharpe LG, Jaffe JH. Captopril and capsaicin modify opioid withdrawal in the morphine-dependent rat. Pharmacol Biochem Behav 1989;33:899-902
19. Walker KM, Urban L, Medhurst SJ, et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;304:56-62
20. Menendez L, Juarez L, Garcia E, Garcia-Suarez O, Hidalgo A, Baamonde A. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 2006;393:70-3
21. Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 2006;12:545-54
22. Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth 2009;102:251-8
23. Hutchinson MR, Coats BD, Lewis SS, et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008;22:1178-89
24. Ma W, Quirion R. Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic pain. Expert Opin Ther Targets 2007;11:307-20
25. Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002;22:6747-55
26. King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005;116:276-88
27. Yue X, Tumati S, Navratilova E, et al. Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner. Eur J Pharmacol 2008;584:272-7
28. Ma W, Zheng WH, Kar S, Quirion R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience 2000;99:529-39
29. Vardanyan A, Wang R, Vanderah TW, et al. TRPV1 receptor in expressionof opioid-induced hyperalgesia. J Pain 2009;10:243-52
30. Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 2007;148:560-72
31. Tiong GK, Pierce TL, Olley JE. Sub-chronic exposure to opiates in the rat: effects on brain levels of substance P and calcitonin gene-related peptide during dependence and withdrawal. J Neurosci Res 1992;32:569-75
32. Gu G, Kondo I, Hua XY, Yaksh TL. Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence. J Pharmacol Exp Ther 2005;314:1362-9
33. Zhou Q, Karlsson K, Liu Z, et al. Substance P endopeptidase-like activity is altered in various regions of the rat central nervous system during morphine tolerance and withdrawal. Neuropharmacology 2001;41:246-53
34. Welch SP, Bass PP, Olson KG, Pugh G. Morphine-induced modulation of calcitonin gene-related peptide levels. Pharmacol Biochem Behav 1992;43:1107-16
35. Trang T, Sutak M, Quirion R, Jhamandas K. The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br J Pharmacol 2002;136:37-48
36. Salmon AM, Damaj MI, Marubio LM, Epping-Jordan MP, Merlo-Pich E, Changeux JP. Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat Neurosci 2001;4:357-8
37. Murtra P, Sheasby AM, Hunt SP, De Felipe C. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 2000;405:180-3
38. Guo A, Vulchanova L, Wang J, Li X, Elde R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999;11:946-58
39. Tang HB, Li YS, Miyano K, Nakata Y. Phosphorylation of TRPV1 by neurokinin-1 receptor agonist exaggerates the capsaicinmediated substance P release from cultured rat dorsal root ganglion neurons. Neuropharmacology 2008;55:1405-11
40. 2+ is involved in the mechanism of distinct substance P release in cultured rat dorsal root ganglion neurons. Naunyn Schmiedebergs Arch Pharmacol 2008;377:325-32